NYSE:AVNS Avanos Medical (AVNS) Stock Forecast, Price & News $23.95 +0.56 (+2.39%) (As of 05/30/2023 ET) Add Compare Share Share Today's Range$23.37▼$24.0350-Day Range$22.53▼$30.9852-Week Range$19.32▼$31.99Volume250,099 shsAverage Volume251,057 shsMarket Capitalization$1.12 billionP/E Ratio26.03Dividend YieldN/APrice Target$30.25 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Avanos Medical MarketRank™ ForecastAnalyst RatingHold2.33 Rating ScoreUpside/Downside26.3% Upside$30.25 Price TargetShort InterestHealthy1.92% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.90Based on 4 Articles This WeekInsider TradingN/AProj. Earnings Growth21.95%From $1.64 to $2.00 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.83 out of 5 starsMedical Sector64th out of 1,009 stocksSurgical Appliances & Supplies Industry6th out of 20 stocks 3.2 Analyst's Opinion Consensus RatingAvanos Medical has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 2 buy ratings, no hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $30.25, Avanos Medical has a forecasted upside of 26.3% from its current price of $23.95.Amount of Analyst CoverageAvanos Medical has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.92% of the float of Avanos Medical has been sold short.Short Interest Ratio / Days to CoverAvanos Medical has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Avanos Medical has recently increased by 1.36%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldAvanos Medical does not currently pay a dividend.Dividend GrowthAvanos Medical does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AVNS. Previous Next 3.8 News and Social Media Coverage News SentimentAvanos Medical has a news sentiment score of 0.90. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.78 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Avanos Medical this week, compared to 3 articles on an average week.Search Interest3 people have searched for AVNS on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat Follows5 people have added Avanos Medical to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Avanos Medical insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.90% of the stock of Avanos Medical is held by insiders.Percentage Held by Institutions92.08% of the stock of Avanos Medical is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 3.8 Earnings and Valuation Earnings GrowthEarnings for Avanos Medical are expected to grow by 21.95% in the coming year, from $1.64 to $2.00 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Avanos Medical is 26.03, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 130.01.Price to Earnings Ratio vs. SectorThe P/E ratio of Avanos Medical is 26.03, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 99.00.Price to Book Value per Share RatioAvanos Medical has a P/B Ratio of 0.86. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Avanos Medical (NYSE:AVNS) StockAvanos Medical, Inc. is a medical technology company. It engages in delivering clinically superior medical device solutions and products to healthcare providers and patients. The company was founded on February 25, 2014 and is headquartered in Alpharetta, GA.Read More Receive AVNS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Avanos Medical and its competitors with MarketBeat's FREE daily newsletter. Email Address AVNS Stock News HeadlinesMay 24, 2023 | americanbankingnews.comAvanos Medical (NYSE:AVNS) Shares Gap Up to $22.53May 24, 2023 | americanbankingnews.comBone Biologics (OTC:BBLG) vs. Avanos Medical (NYSE:AVNS) Financial ReviewMay 30, 2023 | Stocks To Trade (Ad)3 Free Stock Picks per DayUsing our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.May 22, 2023 | msn.comCL King Initiates Coverage of Avanos Medical (AVNS) with Buy RecommendationMay 22, 2023 | finance.yahoo.comAre Investors Undervaluing Avanos Medical, Inc. (NYSE:AVNS) By 47%?May 22, 2023 | americanbankingnews.comAvanos Medical (NYSE:AVNS) Research Coverage Started at CL KingMay 21, 2023 | americanbankingnews.comAvanos Medical (NYSE:AVNS) Receives New Coverage from Analysts at StockNews.comMay 11, 2023 | msn.comAvanos Medical Earnings Perspective: Return On Capital EmployedMay 30, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.May 7, 2023 | americanbankingnews.comStockNews.com Lowers Avanos Medical (NYSE:AVNS) to BuyMay 5, 2023 | msn.comAvanos (AVNS) Q1 Earnings and Revenues Fall Shy of EstimatesMay 5, 2023 | finance.yahoo.comAvanos Medical, Inc.'s (NYSE:AVNS) Share Price Matching Investor OpinionMay 5, 2023 | americanbankingnews.comQ2 2023 Earnings Estimate for Avanos Medical, Inc. (NYSE:AVNS) Issued By KeyCorpMay 4, 2023 | msn.comMorgan Stanley Maintains Avanos Medical (AVNS) Underweight RecommendationMay 4, 2023 | benzinga.comAvanos Medical shares are trading lower after the company reported worse-than-expected Q1 sales results.May 4, 2023 | markets.businessinsider.comMorgan Stanley Reaffirms Their Sell Rating on Avanos Medical (AVNS)May 4, 2023 | americanbankingnews.comAvanos Medical (NYSE:AVNS) Announces Quarterly Earnings ResultsMay 4, 2023 | finance.yahoo.comQ1 2023 Avanos Medical Inc Earnings CallMay 3, 2023 | msn.comRecap: Avanos Medical Q1 EarningsMay 3, 2023 | finance.yahoo.comAvanos Medical (AVNS) Q1 Earnings and Revenues Lag EstimatesMay 3, 2023 | finance.yahoo.comAvanos Medical, Inc. Announces First Quarter 2023 ResultsMay 1, 2023 | americanbankingnews.comShort Interest in Avanos Medical, Inc. (NYSE:AVNS) Decreases By 7.4%April 27, 2023 | marketwatch.comAvanos Medical, Inc. to Webcast Conference Call Discussing First Quarter 2023 Financial ResultsApril 24, 2023 | finance.yahoo.com3 Reasons to Retain HealthEquity (HQY) Stock in Your PortfolioApril 21, 2023 | msn.comAvanos Medical Recalls Certain BALLARD ACCESS Closed Suction Systems For Pediatric Use Citing Ventilation RiskApril 21, 2023 | finance.yahoo.comUS FDA identifies recall of Avanos Medical's respiratory systems as most seriousApril 21, 2023 | seekingalpha.comAvanos Medical: Cost Restructuring Could Unlock Substantial ValueSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive AVNS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Avanos Medical and its competitors with MarketBeat's FREE daily newsletter. Email Address AVNS Company Calendar Last Earnings5/03/2023Today5/30/2023Next Earnings (Estimated)8/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE Industry Surgical appliances & supplies Sub-IndustryN/A SectorMedical Current SymbolNYSE:AVNS CUSIPN/A CIK1606498 Webavanos.com Phone(844) 428-2667FaxN/AEmployees4,044Year FoundedN/APrice Target and Rating Average Stock Price Forecast$30.25 High Stock Price Forecast$34.00 Low Stock Price Forecast$28.00 Forecasted Upside/Downside+28.5%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)$0.92 Trailing P/E Ratio25.60 Forward P/E Ratio14.36 P/E GrowthN/ANet Income$50.50 million Net Margins5.34% Pretax Margin7.06% Return on Equity6.11% Return on Assets4.43% Debt Debt-to-Equity Ratio0.16 Current Ratio2.86 Quick Ratio1.60 Sales & Book Value Annual Sales$820 million Price / Sales1.34 Cash Flow$2.73 per share Price / Cash Flow8.64 Book Value$27.77 per share Price / Book0.85Miscellaneous Outstanding Shares46,670,000Free Float45,314,000Market Cap$1.10 billion OptionableOptionable Beta0.93 Key ExecutivesJoseph F. WoodyChief Executive Officer & Executive DirectorMichael C. GreinerChief Financial & Transformation Officer, SVPLee BurnesSenior VP-Global Research & DevelopmentMichelle ScharfenbergChief Ethics & Compliance Officer, Senior VPMojirade Amanda JamesSecretary, Senior Vice President & General CounselKey CompetitorsEstablishment LabsNASDAQ:ESTASanara MedTechNASDAQ:SMTIVicarious SurgicalNYSE:RBOTEnovisNYSE:ENOVBiomea FusionNASDAQ:BMEAView All CompetitorsInstitutional OwnershipAmeriprise Financial Inc.Bought 21,061 shares on 5/22/2023Ownership: 0.784%Putnam Investments LLCSold 1,324 shares on 5/22/2023Ownership: 0.067%JPMorgan Chase & Co.Bought 9,481 shares on 5/18/2023Ownership: 0.220%New York State Common Retirement FundSold 21,159 shares on 5/18/2023Ownership: 0.075%Thrivent Financial for LutheransSold 1,615 shares on 5/17/2023Ownership: 0.170%View All Institutional Transactions AVNS Stock - Frequently Asked Questions Should I buy or sell Avanos Medical stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Avanos Medical in the last year. There are currently 1 sell rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" AVNS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AVNS, but not buy additional shares or sell existing shares. View AVNS analyst ratings or view top-rated stocks. What is Avanos Medical's stock price forecast for 2023? 3 brokers have issued 12 month price targets for Avanos Medical's shares. Their AVNS share price forecasts range from $28.00 to $34.00. On average, they predict the company's stock price to reach $30.25 in the next year. This suggests a possible upside of 28.5% from the stock's current price. View analysts price targets for AVNS or view top-rated stocks among Wall Street analysts. How have AVNS shares performed in 2023? Avanos Medical's stock was trading at $27.06 on January 1st, 2023. Since then, AVNS shares have decreased by 13.0% and is now trading at $23.55. View the best growth stocks for 2023 here. Are investors shorting Avanos Medical? Avanos Medical saw a drop in short interest in the month of April. As of April 15th, there was short interest totaling 865,700 shares, a drop of 7.4% from the March 31st total of 935,300 shares. Based on an average daily volume of 240,400 shares, the days-to-cover ratio is presently 3.6 days. Approximately 1.9% of the company's stock are short sold. View Avanos Medical's Short Interest. When is Avanos Medical's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023. View our AVNS earnings forecast. How were Avanos Medical's earnings last quarter? Avanos Medical, Inc. (NYSE:AVNS) issued its earnings results on Wednesday, May, 3rd. The company reported $0.27 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.28 by $0.01. The business earned $191.70 million during the quarter, compared to analyst estimates of $195.20 million. Avanos Medical had a trailing twelve-month return on equity of 6.11% and a net margin of 5.34%. The business's revenue was down 2.9% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.26 earnings per share. What ETFs hold Avanos Medical's stock? ETFs with the largest weight of Avanos Medical (NYSE:AVNS) stock in their portfolio include Invesco S&P SmallCap Health Care ETF (PSCH), SPDR S&P Health Care Equipment ETF (XHE), ROBO Global Healthcare Technology and Innovation ETF (HTEC), First Trust Active Factor Small Cap ETF (AFSM), Royce Quant Small-Cap Quality Value ETF (SQLV), First Trust Small Cap Value AlphaDEX Fund (FYT), iShares S&P Small-Cap 600 Value ETF (IJS) and SPDR S&P 600 Small CapValue ETF (SLYV). What guidance has Avanos Medical issued on next quarter's earnings? Avanos Medical issued an update on its FY 2023 earnings guidance on Wednesday, May, 3rd. The company provided EPS guidance of $1.60-$1.80 for the period, compared to the consensus EPS estimate of $1.70. The company issued revenue guidance of -. What is Joseph F. Woody's approval rating as Avanos Medical's CEO? 32 employees have rated Avanos Medical Chief Executive Officer Joseph F. Woody on Glassdoor.com. Joseph F. Woody has an approval rating of 51% among the company's employees. This puts Joseph F. Woody in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Avanos Medical own? Based on aggregate information from My MarketBeat watchlists, some companies that other Avanos Medical investors own include Kimberly-Clark (KMB), CVS Health (CVS), Pfizer (PFE), Procter & Gamble (PG), Johnson & Johnson (JNJ), Raytheon Technologies (RTX), AT&T (T), Abbott Laboratories (ABT) and Alibaba Group (BABA). What is Avanos Medical's stock symbol? Avanos Medical trades on the New York Stock Exchange (NYSE) under the ticker symbol "AVNS." Who are Avanos Medical's major shareholders? Avanos Medical's stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (15.98%), Dimensional Fund Advisors LP (6.80%), State Street Corp (4.34%), Macquarie Group Ltd. (4.26%), Geode Capital Management LLC (1.88%) and Charles Schwab Investment Management Inc. (1.42%). View institutional ownership trends. How do I buy shares of Avanos Medical? Shares of AVNS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Avanos Medical's stock price today? One share of AVNS stock can currently be purchased for approximately $23.55. How much money does Avanos Medical make? Avanos Medical (NYSE:AVNS) has a market capitalization of $1.10 billion and generates $820 million in revenue each year. The company earns $50.50 million in net income (profit) each year or $0.92 on an earnings per share basis. How many employees does Avanos Medical have? The company employs 4,044 workers across the globe. How can I contact Avanos Medical? Avanos Medical's mailing address is 5405 Windward Parkway Suite 100 South, Alpharetta GA, 30004. The official website for the company is avanos.com. The company can be reached via phone at (844) 428-2667 or via email at investor.relations@avanos.com. This page (NYSE:AVNS) was last updated on 5/30/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avanos Medical, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.